| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Anika Therapeutics Inc (NASDAQ: ANIK)
ANIK Technical Analysis
2
| As on 9th Jun 2023 ANIK SHARE Price closed @ 27.60 and we RECOMMEND Buy for LONG-TERM with Stoploss of 26.14 & Strong Sell for SHORT-TERM with Stoploss of 32.85 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ANIKSHARE Price
| Open | 26.82 | Change | Price | % |
| High | 27.74 | 1 Day | 0.79 | 2.95 |
| Low | 26.78 | 1 Week | 0.51 | 1.88 |
| Close | 27.60 | 1 Month | 1.80 | 6.98 |
| Volume | 39988 | 1 Year | -9.85 | -26.30 |
| 52 Week High 37.99 | 52 Week Low 20.40 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ANIK Daily Charts |
ANIK Intraday Charts |
Whats New @ Bazaartrend |
ANIK Free Analysis |
|
|
ANIK Important Levels Intraday
| RESISTANCE | 29.45 |
| RESISTANCE | 28.86 |
| RESISTANCE | 28.49 |
| RESISTANCE | 28.12 |
| SUPPORT | 27.08 |
| SUPPORT | 26.71 |
| SUPPORT | 26.34 |
| SUPPORT | 25.75 |
ANIK Forecast April 2024
| 4th UP Forecast | 40.01 |
| 3rd UP Forecast | 36.03 |
| 2nd UP Forecast | 33.57 |
| 1st UP Forecast | 31.11 |
| 1st DOWN Forecast | 24.09 |
| 2nd DOWN Forecast | 21.63 |
| 3rd DOWN Forecast | 19.17 |
| 4th DOWN Forecast | 15.19 |
ANIK Weekly Forecast
| 4th UP Forecast | 33.25 |
| 3rd UP Forecast | 31.44 |
| 2nd UP Forecast | 30.32 |
| 1st UP Forecast | 29.20 |
| 1st DOWN Forecast | 26.00 |
| 2nd DOWN Forecast | 24.88 |
| 3rd DOWN Forecast | 23.76 |
| 4th DOWN Forecast | 21.95 |
ANIK Forecast2024
| 4th UP Forecast | 63.17 |
| 3rd UP Forecast | 51.76 |
| 2nd UP Forecast | 44.71 |
| 1st UP Forecast | 37.66 |
| 1st DOWN Forecast | 17.54 |
| 2nd DOWN Forecast | 10.49 |
| 3rd DOWN Forecast | 3.44 |
| 4th DOWN Forecast | -7.97 |
Anika Therapeutics Inc ( NASDAQ USA Symbol : ANIK )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ANIK Business Profile
Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts. Address: 32 Wiggins Avenue, Bedford, MA, United States, 01730
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service